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The host range of poxviruses is highly regulated and is limited to
certain hosts. A number of genes in different poxviruses have been identified
that contribute to cell tropism. The ankyrin (ANK) repeat genes encode for

proteins characterized by the repetitive motifs in its amino acid sequence.

These genes have been found to play a role in determining the ability of
poxviruses to replicate in certain cell types. Tanapoxvirus (TPV) Kenya

genome analysis indicated the presence of six ANK repeat genes of which
T146R, T147R and T148R are present in the terminal part of the TPV-Kenya

genome. To understand the possible role of T146R in determining the cell
tropism, an insertional knockout TPV (TPV-AT146R) was constructed. The
ability of TPV-AT146R to replicate in a variety of human colorectal cancer cell
lines and human malignant melanoma cells was also tested. Cell monolayers
were observed for viral cytopathic effect at 96 hours post infection (h.p.i.)
indicated that both TPV-Kenya and TPV-AT146R replicated in most of the
human colorectal cancer cell lines. Taken together, these results provide

evidence that the open reading frame T146R in TPV is a non-essential gene.
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INTRODUCTION

Ankyrin repeat containing proteins were first reported in 1978, as a

protein present on the membrane of erythrocytes which act as anchor
proteins, hence named as ankyrin (ANK) proteins (Bennett, 1978). A repeat of
~33 amino acid residues was observed in the sequence of two cell-cycle

regulators Swi6p and CdclO, in yeast and a developmental regulator Notch in
Drosophila melanogaster (Breeden and Nasmyth, 1987). Later on, multiple
copies of a similar sequence were reported in the cytoskeletal protein ANK

(Lux et al., 1990). Subsequently, ANK proteins were also reported to be
present in a wide range of organisms from prokaryotes to eukaryotes. Based
on further studies, the role of ANK proteins in mediating interaction between

different proteins is well known and they have been found to be present in a

variety of proteins like transcriptional mediators, developmental regulators,
cytoskeletal organizers, cyclin-dependent kinase inhibitors and toxins. In
addition, the role of ANK proteins in protein-protein interaction is not limited

to a particular class of proteins but instead it has been found to be involved
with a wide variety of proteins (Michaely and Bennett, 1992; Bork, 1993).
ANK proteins have been shown to play an important role in expression,

localization and regulation of ion channels and transporters in the cardiac cell
membrane. Mutations or loss of these ANK genes have been linked to the

development of cardiac arrhythmias (Cunha and Mohler, 2011). In addition,
ANK proteins have also proven to be of great importance for multiple aspects
of muscle function. They play a critical role at different stages of muscle
development and in controlling the hypertonic responses in fully developed
muscles, thus suggesting the importance of these proteins in the

developmental disorders of muscle (Tee and Peppelenbosch, 2010).

Additionally, some ANK proteins have a role in the transduction of
endogenous inflammatory factors, as well as exogenous irritating chemicals,
such as the Transient Receptor Potential Ankyrin 1 (TRPA1) on non
myelinated pain receptors (Stucky et al., 2009).

Chordopoxviruses (poxviruses of vertebrates) encode a

large number of ANK proteins and typically the terminal part of their large
linear DNA is responsible for coding them. Amongst these viruses,

Molluscum contagiosum virus is the only poxvirus to date, which does not
encode for any ANK proteins. Certain ANK proteins from vaccinia virus

(VACV), myxoma virus (MYXV) and cowpox virus (CPXV) have been
studied and they have shown to play a role in determining the virulence and
host tropism of these viruses. Still the role of many other ANK proteins

encoded by Chordopoxviruses remains a mystery and need to be studied
further (Sonnberg et al., 2011).

This study describes the potential role of ANK repeat

genes, T146R in TPV as a host/cell range factor. The T146R knockout TPV

(TPV-AT146R) was generated and tested for its ability to replicate in a bank of
human cancer cell lines, owl monkey kidney cells (OMK) and human fetal

lung fibroblasts (WI 38). The OMK and WI38 cells served as a control.

REVIEW OF LITERATURE

Tanapoxvirus

Poxviruses are large DNA viruses which infect a wide range of hosts.

They replicate in the cytoplasm of the host cells and carry a double stranded
DNA genome. While the central part of genome is highly conserved, the
terminal part of poxvirus genomic DNA is considerably divergent and bear

the genes that encode proteins involved in host specificity and virulence.
Poxvirus family is divided into two subfamilies, namely Entomopoxvirinae
which infect insects and Chordopoxvirinae which infect vertebrates.

Chordopoxviruses are further divided into eight genera, Orthopoxvirus,
Parapoxvirus, Leporipoxvirus, Capripoxvirus, Avipoxvirus, Suipoxvirus,

Molluscipoxvirus and Yatapoxvirus (Knipe and Howley, 2007). TPV belongs

to the genus Yatapoxvirus which also includes two more members, namely
Yaba-like disease virus (YLDV) and Yaba monkey tumor virus (YMTV). All
the members of Yatapoxviruses replicate in closely related hosts. Monkeys
are the host for YLDV and YMTV while TPV replicates in humans (De

Harven and Yohn, 1966; Espana et al., 1971). TPV and YLDV genomes are

very closely matched (98.6%), showing similarity levels on par with different
strains of VACV; it has therefore been argued that TPV and YLDV are

possibly different strains of the same virus. In TPV-Kenya, T8L, T11.1L,
T11.2L, T146R, T147R and T148R are the ANK repeat genes that have been

identified and may potentially play a role in determining the host range
(Nazarian et al., 2007).

A disease caused by TPV was reported in 1957 in Nagu village, in the

flood plains of the Tana river in Kenya. Two widespread epidemics in 1957
and 1962 of TPV disease occurred in the region along Tana river. Analysis of

biopsy specimens from the skin legions showed that the virus belongs to the
poxvirus group but differ from other poxviruses and hence named as TPV.
TPV has a very limited range of hosts and has been grown in human and

monkey tissues successfully. Monkeys are the only animal found to be
susceptible to TPV (Downie et al., 1971). Recently a case of TPV infection was

reported in 2004 in a college student who was caring for chimpanzees and
spent time in close proximity with them in Republic of Congo (Dhar et al,
2004). These instances suggest towards possibility of TPV being a zoonosis

from monkeys to humans. In another instance, after spending 3 weeks in
Tanzania, a patient reported being infected with TPV in Europe in 1999.
Though the infection was suspected to be a zoonosis from mosquito or cat

during his stay in Tanzania, the mechanism of transmission and the animal
reservoir of the disease couldn't be confirmed (Stich et al, 2002). Another case

of TPV infection was reported in 2002, in a traveler from Sierra Leone

(Croitoru et al, 2002). After an outbreak of YLDV in some primate centers in
the U.S. in 1966, some animal handlers were infected, possibly through the

skin lesions (Downie and Espana, 1972). This supports the possibility of TPV
infection being a zoonosis from animals to humans as both TPV and YLDV
are the members of Yatapoxvirus genus. In humans, TPV causes a short
febrile disease accompanied by few skin lesions, severe headache, backache

and prostration. This was followed by development of macular or nodular
skin lesions where some of the nodular skin legions may burst due to trauma

or necrosis, developing into an ulcer. However the disease caused by TPV is

self-limiting (Jezek et al., 1985).

Ankyrin Repeat Proteins in Poxviruses

Ankyrin repeat proteins are the adaptor proteins which contain
repetitive motifs of about 33 residues. Recently it has been shown that ANK
proteins with F-box motif at C-terminal are capable of interacting with SCF-1
ubiquitin ligase complex through the adapter subunit SKP1 of the complex.

This suggests that the ANK proteins are possibly manipulating the host cell's
ubiquitin system by directing it towards specific proteins (Sonnberg et al.,
2008). CPXV expresses an ANK protein CPXV-006 which has been shown to
manipulate the host immune response by inhibiting NF-kB which plays a role
in activation of immune response following infection and cell injury. This
further supports the idea that just like many other viruses and bacteria,
poxviruses have evolved these novel mechanisms to counter the host immune
system (Mohamed et al., 2009). M-T5, an ANK protein encoded by MYXV has

been demonstrated to interact with the host cell cullin-1 which is a cell cycle

regulator. Host cell cullin-1 plays a role in the regulation of cell cycle through
alteration of p27/kip-l phosphorylation. This suggests a possible role of ANK
protein M-T5 as a cell cycle regulator (Johnston et al., 2005). ANK proteins,
M148R and M149R in MYXV have been demonstrated to be critical in

determining the virulence. MYXV showed a drastic decrease in virulence
when the genes encoding M148R and M149R were knocked out, although

they didn't seem to affect the tissue tropism and host range (Blanie et al.,
2009).

Cancer

Cancer is a group of diseases characterized by uncontrolled growth of
cells which can spread from the site of origin to distant sites in the body.
Cancer can be the result of point mutation or shift in the genome which can

possibly be caused by physical, chemical and biological agents. Some of the
known possible causative factors of cancer are UV light (physical agent),
asbestos, dye, poly vinyl chloride (chemical agents), Viruses and bacterium

(biological agents). It has been observed for most of the cancers that the risk
of developing cancer increases with age, and middle aged and old aged
population is mostly affected. Genetic makeup also plays a role by
predisposing individuals with specific genes to certain types of cancer like
BRCAl and BRCA2 genes in breast cancer. Cancer has been a growing health
concern due to the high incidence and mortality associated with it.

In the U.S. the age adjusted mortality rate of cancer is 178.7 per 100,000
men and woman per year. Most common cancers are lung cancer, colorectal
cancer (CRC) and skin cancer, in addition, breast cancer (BC) in females and

prostate cancer in males. CRC is the second highest cause of cancer related
deaths while BC is one of the most frequently diagnosed cancers in women in

US and is ranked second highest as a cause of cancer related deaths in

women. According to the National Cancer Institute the age adjusted
incidence rate of CRC is 46.3 per 100,000 men and woman per year and BC is
124.3 per 100,000 women per year in US. The age adjusted annual mortality
rates for CRC and BC are 16.7 per 100,000 men and women and 23 per 100,000
women respectively (Howlader et al., 2012)

Diagnosis of cancer at an early stage is very important to improve the

survival rate as metastasis at advanced stage creates complications leading to

death. Conventional diagnostic techniques that are currently used include;
clinical examination, screening techniques like proctoscopy, mammography
or CAT scans and histopathological examination of biopsy from the tissue.

American Cancer Society has recommended some guidelines and runs

awareness campaigns to increase the chances of detecting cancer at early
treatable stages and improve survival rate. The treatment strategy for cancer
is determined based on the stage at which cancer has been diagnosed and the
conventional treatment options available for advanced cancers involve

surgical treatment followed by radiotherapy and/or chemotherapy, but
serious side effects associated with radiotherapy and chemotherapy limit

their use. In addition adjuvant therapies like the use of Tamoxifen can be

used in patients with breast cancer positive for Estrogen Receptors (ER).
Oncolytic virotherapy is a relatively new option which seems to be promising
but still under clinical trials. Effective measures to control the metastatic

disease in advanced stages of cancer are the key to improve the survival rate
and quality of life.

Oncogenes, Growth Factors and Secondary Signaling

Epidermal growth factor receptor (EGFR) is known to play a role in
progression of tumor through activation of many signaling pathways that
eventually result in cellular growth, angiogenesis, invasion and metastasis.
The exact mechanism through which EGFR plays role in carcinogenesis is not

completely understood, but amplification of genes is supposed to be
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responsible for their overexpression. Altered expression of EGFR has been
linked with BC, CRC, non-small cell lung carcinoma, pancreatic cancer, brain

cancer and squamous cell carcinomas in the head and neck region (Brand et
al., 2011).

Overexpression of HER-2/neu/erbB2 has been linked with cancer and
the overexpression is possibly due to amplification of the gene. It has been
observed that overexpression of HER-2 is associated with higher rate of
lymph node metastasis, growth of tumor and decreased survival rate in

cancer patients (Tsapralis, 2012; Lee et al, 2007). HER-2 overexpression has
been noticed in the cancer tissue of both ductal carcinoma in situ and invasive

ductal carcinoma, but interestingly HER-2 is very highly overexpressed in the
ductal carcinoma in situ as compared to the invasive ductal carcinoma. This
indicates towards a possible role of HER-2 in progression of ductal carcinoma

in situ, a comparatively benign state to a highly malignant invasive ductal
carcinoma. However, it has been found that development of vascular stroma

in the adjacent tissue can be an important factor leading to invasion of ductal
carcinoma in situ into adjacent tissue and HER-2 gene expression doesn't

always play a significant role in progression of a tumor from a relatively
benign to highly malignant state (Latta et al., 2002).

Another oncogene, c-Myc has been associated with the metastasis of
the cancer cells. It promotes metastasis indirectly by favoring cancer cell
growth, cell survival, genetic instability and angiogenesis. However, c-Myc
has also been found to regulate metastasis through a more direct and indirect

ways by manipulating downstream programs involving activation of SNAIL
transcription factor through TGF-p, as reviewed in (Wolfer and Ramaswamy,

2011). The gene c-Myc has been reported to be amplified in ductal carcinoma
in situ significantly and in few cases of invasive ductal carcinoma. The exact
mechanism through which it is overexpressed is not yet clearly known. Co-

amplification of HER-2 in most of the cases expressing altered c-Myc
oncogene has been reported (Aulmann et al., 2002).

Cyclin Dl oncogene is overexpressed at all the stages during the
development

of

ductal

carcinoma

of

breast,

beginning

from

hyperproliferative state of ductal epithelium of breast through ductal
carcinoma in situ to invasive carcinoma of breast, cyclin Dl is overexpressed

at all the stages. However, cyclin Dl expression is increased gradually from
hyperproliferative state to invasive ductal carcinoma state, indicating that it

plays an important role in development as well as progression of ductal
carcinoma of breast (Alle et al, 1998). Cyclin Dl acts as a cell cycle regulator
and overexpressed in many cancers. It regulates cell cycle by acting as a

sensor for mitogenesis and activating factor for cyclin dependent kinase
(CDK) 4/6. In neoplastic cells the nuclear trafficking of Cyclin Dl is impaired
resulting in accumulation of Cyclin Dl inside the nucleus. High nuclear

levels of Cyclin-Dl along with proteolysis are believed to be the reasons for
the development of cancer (Kim and Diehl, 2009). This indicates that
overexpression of cyclin Dl is not the sole factor for development of cancer,
but its accumulation inside the nucleus plays a huge role.

Transforming growth factor- beta (TGF-p) is an important factor

playing crucial roles in regulation of cell growth. Loss of functional TGF-preceptor II has been linked with proliferation of tumor cells (Gobbi et al.,
1999). In addition to EDGF, estrogen is another important hormone which
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plays an important role in development of ductal carcinomas which are

positive for estrogen receptors. Though the exact mechanism through which
estrogen induces the growth in ductal carcinoma is not completely known,
but it is believed that it acts through an indirect pathway (Palmieri et al,
2002). Different cytokines like IL-2, IL-6 and TNF- a has been reported to play
an important role in carcinoma development by promoting growth of cells

through different mechanisms (Garcia-Tunon et al., 2004; Garcia-Tunon et al.,
2006).

The surrounding stromal tissue in ductal carcinoma of breast differs
from that of normal breast tissue. Though the stromal tissue doesn't become

malignant itself, it has been noted that different isoforms of extra-cellular
glycoprotein called Tenascin are expressed at different stages during

progression of cancer. These altered forms of Tenascin produced by stromal
tissue adjacent to the cancerous tissue are believed to be responsible for the
progression

of

cancer

by

promoting

development

of

anchorage

independence, invasion of cancer cells into the surrounding tissue and
angiogenesis (Adams et al., 2002).

Tumor Suppressor Genes

The p53 is a commonly altered tumor suppressor gene by mutations in
many cancers. Function of p53 gene is altered by missense mutation or
nonsense or frameshift mutations result in loss of p53 gene functionality
which makes it ineffective In terms of tumor suppression activity, resulting in

development of oncogenesis (Vogelstein and Kinzler, 1992). Oncogene p53 is
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known to regulate plasticity, synthesis, repair and transcription of DNA and
cellular apoptosis as reviewed in (Greenblatt et al., 1994).
BRCAl and BRCA2 are two major tumor suppressor genes which

regulate the cell growth. BRCAl gene is believed to be responsible for most of
the familial or hereditary cases of breast cancer, while a smaller proportion of
familial breast cancer cases are linked with BRCA2 gene (Easton et al., 1993;
Miki et al., 1994; Wooster et al., 1994). It is believed that these tumor

suppressor genes encode a regulatory protein that inhibits the cell growth
and keeps the cell division under control. Loss of functionality is usually due
to the mutations in these tumor suppressor genes which result in either non-

production of the proteins or production of an altered form of protein with
reduced or abolished function. Missense mutations are responsible for these

alterations in these tumor suppressor genes most of the time (Miki et al.,

1994). Another mechanism through which BRCAl has been suggested to play
a role is by regulating the activity of p27 and p21. Proteins p27 and p21 are
believed to inhibit the cell growth and promote apoptosis by inhibiting the
CDKs (Williamson et al, 2002). It has been observed that BRCAl trans-

activates the production of p21. Thus BRCAl acts through regulation of p21
activity and causes arrest of cell cycle. This arrest of cell cycle caused by
BRCAl has been observed in the transformed cells (Somasundaram et al.,

1997). In a normal breast tissue BRCAl causes an up-regulation of p27 and
keeps a check on cell division. In a cancerous tissue low levels of p27 have
been observed as compared to normal tissue which shows that the mutations

in BRCAl gene might be rendering this mechanism inefficient to control the

cell growth, leading to transformation of normal cells. Thus a decrease in the
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level of p27 in breast tissue indicates towards a possible incompetent BRCAl

gene. Recently it has been suggested that methylation of BRCAl gene can also

be responsible for alteration of expression of BRCAl gene. Methylation of
BRCAl gene has been linked to down-regulation of expression of p27. It is
quite possible that methylation or mutations or both the mechanisms together
render BRCAl gene inefficient to control the cell growth (Chappuis et al.,
2000; Niwa et al, 2000).

Researchers have been trying to understand the interaction between

p53 and BRCAl and its effect on regulation of cell cycle. BRCAl is found to
be involved in both p53 dependent as well as p53 independent transcription

regulatory mechanisms. BRCAl leads to transcriptional co-activation of p53
gene which causes increased expression of p21 and bax gene. Gene BRCAl

and p53 are the important factors in cell cycle regulation and apoptosis of
cells. In normal breast tissue BRCAl coded protein binds to the p53 and

induces apoptosis in cancer cells. In patients with familial breast cancer the
mutations in BRCAl gene, truncated forms of protein are produced which

competes for binding sites on p53 and interferes with the activation of the
same. This results in inhibition of apoptosis in cancer cells by causing down-

regulation of p21. It has been observed that BRCAl binds with p53 in vivo as
well as in vitro which supports the above hypothesis (Zhang et al, 1998).
In addition to BRCAl and BRCA2, pi6 and Rb tumor suppressor genes

are found to be involved in development of carcinoma. Oncogenesis can be
the result of an altered pl6-Rb pathway in some of the cancers. The gene

CDKN2 encodes for pi6 and can be inactivated by deletion mutations and

hypermethylation of genes (Gorgoulis et al., 1998). Transcription factor E2F
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has been shown to interact with Rb, which suggests that alteration of pi6-

cyclin Dl-Rb pathway can be linked to oncogenesis. Inability of altered Rb
gene to interact with E2F can result in deregulation of E2F function and result
in the development of cancer (Bernards, 1997).

Apoptosis

Apoptosis is a programmed cell death which can be triggered by
different gene products. It is a highly regulated by fine balancing between the
promoters and inhibitors of apoptosis. Apoptosis plays an important role as
an important defense mechanism against infection and cancer development.

The apoptotic process is triggered in a cell followed by infection with viruses
as well as after transformation of normal cells into cancerous cells. Bcl-2 gene

family has emerged as an important group of genes which control the
apoptosis. The exact mechanism through which they act is a controversial
issue, but it has been suggested that Bcl-2 prevents apoptosis by altering the

damage caused by reactive oxygen radicals. It has also been found that the
Bcl-2 genes avoid apoptosis in the cells lacking mitochondrial DNA. Cancer
cells lack mitochondrial DNA and so have a deficient oxidative respiratory

chain. The Bcl-2 gene is overexpressed in cancer cells, but less likely to act by
avoiding the oxidative damage to cells (Jacobson et al, 1993). The bcl-2family
members interact with each other to regulate the apoptotic activity in the
cells. The Bax is another member of the Bcl-2 family and is a homologous to
Bcl-2 and has been known to bind with Bcl-2 and inhibit the Bcl-2 anti-

apoptotic activity (Oltvai et al., 1993). The Bcl-2 family members consist of
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promoters and inhibitors of apoptosis. Interaction among these promoters
and inhibitors from Bcl-2 family makes apoptosis a highly regulated activity.

The Bcl-2 genes also interact with the non-family members like IGF-II and
cytokines to control the apoptosis (Christofori et al., 1994).

Another tumor suppressor which plays a key role in the regulation of

apoptosis process is p53. It plays a role in multiple crucial events of cell life
like transcription regulation, promoting apoptosis of cell, gene stabilization,

inhibition of cell cycle progressionand angiogenesis. Mutations in p53 lead to
loss of its function to promote the apoptosis in cells. Cancer cells can bypass

the apoptosis following transformation due to mutated p53 gene (Simpson

and Page, 2000). It is believed that p53 has a nuclear binding site through
which it can activate target elements. Another possible way through which

p53 can act is by promoting oncogenesis through up-regulation of p21 which

is a cyclin dependent kinase inhibitor (Bernards, 1997). The p53 is also found
to repress the expression of Bcl-2 which inhibits apoptosis (Miyashita et al.,
1994). The Rb gene is another tumor suppressor gene which is also found to
be altered in few cases during development of malignancies. It has been

found that mutations in the Rb gene cause abnormal DNA development
which in turn triggers apoptosis of the cells (Morgenbesser et al., 1994).

Recently the zinc finger transcription factors - snail and slug were found to be
involved in the development of invasive ductal carcinoma. One possible way

through which they can act is through repression of E-cadherin which is
believed to be an important factor playing a role by altering the invasiveness

of tumor cells. Slug is also found to play a key role in the maintenance of
poorly differentiated cells and promote the growth of cancer tissue. Also
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these gene expressions have been found to be regulated by different factors
like estrogen, EGF/EGFR and c-kit pathways (Come, 2004).

Genomic Integrity

In a normal cell the rate at which mutations take place in the genome is

significantly low. It is believed that the rate of mutation in a normal cell is as
low as one mutation for everylO6 number of cell divisions (Strauss, 1992).

Different protective mechanisms to counteract these mutations involve repair

of the genome or induction of cell cycle arrest and apoptosis. This makes
mutation a relatively rare event in a normal cell. The cells when transformed
from normal to cancerous cells show an increased level of mutation events

leading to an increasing number of defects in DNA due to possible failure of
the DNA repair system. The cellular genome becomes unstable resulting in an
uncontrolled growth of tumor cells (Jacinto and Esteller, 2007).
Passage of a cell from one phase to another phase during replication is

a highly regulated procedure and many genes play crucial roles in it.
Amongst various factors controlling the cell cycle progression, cyclins and
cyclin dependent kinases exhibit vital roles in cell cycle progression. It is now

clearly known that the CDK inhibitors play an important role in the
regulation of CDK activity in response to different signals received from
within the cell and from the surrounding environment of the cell. All these

factors along with replication enzymes ensure the homogeneous distribution

of the replicated genome between the two daughter cells. Mutations in any of
these genes regulating the smooth and successful passage of cells through
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different phases during the replication cycle leads to DNA damage and
transformation of normal cells (van den Heuvel, 2005).

The checkpoint system plays an important role in the assessment of
genomic integrity during the passage of cells from one phase to another
during replication. The altered genome due to either mutations or replication
errors are detected by the checkpoint system and the cell cycle progression is

stopped allowing some time for a cell to repair the altered genome. Thus the

checkpoint system ensures that all the necessary events are completed before
the cell enters into the next phase (van den Heuvel, 2005). Many tumor

suppressor genes like ATM, NBS1, BRCAl and BRCA2 are found to play a
crucial role in the maintenance of genomic integrity through the checkpoint

system. At Gl-S checkpoint the p53 plays an important role and causes a cell
cycle arrest in case of any DNA damage (Dasika et al., 1999). ATM is found to
act by up-regulating the expression of p53 which is another tumor suppressor

in response to damage to the DNA (Meulmeester et al., 2005). This indicates
that ATM basically acts as a caretaker gene and helps to maintain the
genomic integrity.

Along with tumor suppressor genes p53 and ATM, the other two

genes which have been found to play a central role in DNA repair are hMSH2
and hMLHl. Inactivation of these genes leads to a higher rate of mutations
which are successfully carried further to the daughter cells. This mutated
aberrant DNA leads to the uncontrolled growth of cancer cells (Murata et al.,

2002). Thus the DNA repair mechanisms, cell cycle control mechanisms and

checkpoint mechanisms at different phases of the cell cycle work together to
avoid the mutations and maintain the integrity of genome.
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Metastasis

Metastasis of tumor cells to distant locations involves mainly three

steps: detachment, invasion and migration. The tumor cells are attached to
surrounding cells through glycoproteins like laminin and firbonectin. Tumor

cells finely regulate the activities of these attachment proteins as they need to
increase or decrease their level of activity at different stages of the

development of cancer since they have to attach and detach to the

surrounding cells at different stages (Jones and DeClerck, 1980). Tumor cells
invade the surrounding tissue by hydrolysis of the surrounding matrix by a
group of proteolytic enzymes like metalloproteinases (MMPs). Tumor cells
and the surrounding stromal cells secrete the MMPs (Jones and DeClerck,
1980; Liotta et al., 1977). These proteolytic enzymes together play an

important role in extra-cellular matrix membrane remodeling. The proteolytic
activity appears to be highly localized adjacent to the tumor cell which is
invading the anatomical barriers to enter into the circulatory system (Liotta,
1984; Yee and Shiu, 1986). Recent study indicates that the activity of MMP's is
finely regulated by tissue inhibitors of the matrix metalloproteinases (TIMP)
(Vizoso et al, 2007).

Metastasis involves migration of the tumor cell through the anatomical
barriers into the circulatory system. The cancer cells, after progressing to

invasive stage initially metastasizes to axillary and internal mammary lymph
nodes which are draining the tissue. The common distant sites where they
metastasize are liver, lungs, skeleton and central nervous system (Aragon-

Ching and Zujewski, 2007). Metastasis of ductal carcinoma of breast cells to
distant sites is a sequential process as the cells have to cross multiple
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anatomical barriers like basement membrane, stroma and the vessel wall to

enter into the circulatory system. The tumor cells are further carried to distant

sites where they form secondary tumors. Before crossing the anatomical
barriers, the tumor cells have to free themselves from surrounding tumor

cells. E-cadherin is a calcium dependent trans-membrane protein that plays

an important role in the attachment of the cell surface. Tumor cells in invasive
ductal carcinoma of the breast express an aberrant E-cadherin which allows
the tumor cells to break their attachments with other tumor cells in the

primary tumor mass. Aberrant expression of E-cadherin in the tumor cells
possibly enables them to cross the vessel or lymphatic channel wall to enter

into the circulatory system. E-cadherin is found to be re-expressed by the
tumor cells when they reach the distant sites allowing them to attach with the
other cells at the secondary site and colonize to form a secondary tumor.

Highly regulated expression of E-cadherin plays an important role during
metastasis (Kowalski et al., 2003). In addition, the chemokines promote the
invasion of the tumor cells into surrounding tissue and into the circulatory

system. The chemokines and chemokine receptors like CXCR4, CXCR1,
CXCR6 and CXCR7 also regulate the migration of metastatic cells to the
specific distant sites and their successful colonization at the secondary sites.
These specific chemokine receptors show high density at the possible
secondary sites of metastasis, making a favorable environment for the tumor
cells to colonize. Chemokines have been found to be playing an essential role

in terms of induction of angiogenesis which is a critical step in the formation
of secondary colonies (Karnoub and Weinberg, 2006). It appears that
chemokines play important roles at all the stages of metastasis, beginning
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from the invasion of tumor cells from primary tumor mass into the
circulatory system to their colonization at distant secondary sites.

Host Tropism of Poxviruses

Poxviruses are able to infect relatively wide range of eukaryote hosts

except Molluscum contagiosum virus which is highly host restricted.

However each family within the poxvirus group is restricted to limited hosts
(McFadden, 2005). Poxviruses encode certain host range proteins which are

believed to play a role in determining their tissue tropism. Host cells that are
permissive to certain poxviruses support the successful replication of viruses
inside the cell by providing the required factors. It has been suggested that
the host range proteins work by manipulating with certain intracellular

pathways of the host cells and compromising the anti-viral defense
mechanisms of the host, creating a favorable environment for the viruses to

replicate successfully. This suggests that in non-permissive cells, the virus
fails to replicate successfully due to either lack of the host factors or its

inability to manipulate anti-viral pathway mechanisms of the host cell.
(Werden et al, 2008) Creating specific gene-knockout virus and testing their

ability to replicate in the cells permissive to wild type virus has been a
commonly used strategy for identification of the host range genes.

Vaccinia Virus Ankyrin Repeat Gene KIL

In a study to determine the genes responsible for the replication of
VACV in human cells, a knock-out KIL VACV which lost its ability to
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replicate in human cells was able to regain it after inserting 855bp long DNA
fragment from the wild-type VACV. This DNA insert from wild-type VACV

contained only KIL open reading frame (ORF) (Gillard, 1986). Though the
exact mechanism of action is not completely clear, KIL gene appears to play a

direct or indirect role during the production of early delayed viral gene

products. (Gillard et al., 1989) Modified vaccinia virus (MVA) lacking KIL

gene was able to successfully replicate, when KIL was ectopically expressed
in transfected RK13 cells, which otherwise was unable to replicate in RK13

cells. This supports the role of KIL as host range gene. (Sutter et al, 1994)
KIL interacts with host factors like ACAP2, which is a GTPase

activating protein (Bradley and Terajima, 2005; Meng and Xiang, 2006). KIL
has been shown to inactivate NF-kB by degradation of IkBa which can be a

possible mechanism of action for KIL to regulate the host tropism (Shisler
and jin, 2004). However, later studies have indicated that this is a less likely
mechanism of action for KIL as a double-knockout VACV lacking KIL and

C7L, another host range gene in VACV, could not be rescued even after
knockdown of NF-kB in Hela cells (Chang et al., 2009). Recently KIL has been

shown to inhibit anti-viral response induced by type I interferon (INF) in the

host cells. Replication of VACV double-knockout which lacked both KIL and
C7L was blocked at the intermediate stage of viral gene translation in the cells

pre-treated with type I INF. However, the virus regained its INF- resistant
phenotype with restoration of Kl-L or C7L (Meng et al., 2009). KIL is an
ANK repeat gene in VACV and most of the Orthopoxviruses encode ortholog

genes, indicating that it has been conserved fairly well amongst
Orthopoxviruses (Werden et al., 2008).
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Vaccinia Virus Ankyrin Repeat Gene C7L

C7L is another host range protein encoding gene in VACV which is

functionally equivalent to the KIL gene. Ability of VACV strainCopenhagen

to replicate in human cells after deletion of KIL gene indicated towards a
possibility of presence of another functionally equivalent gene. Further
investigation led to the discovery of C7L gene. Although C7L was able to
retain the potential of VACV strainCopenhagen to replicate in human cells, it
failed to do the same in rabbit cells RK13 (Perkus et al, 1990). This indicates

that though KIL and C7L are functionally equivalent genes present in the
VACV, their presence helps the virus to widen its host range. Recent study
has shown that C7L inhibits the induction of apoptosis of the infected host
cell. NYVAC is a knockout virus obtained from VACV strain Copenhagen

which lacks both KIL and C7L. NYVAC failed to prevent an increase in the

rate of phosphorylation of eIF-2a, a eukaryotic protein synthesis initiation
factor which coincided with the shutdown of translation process. Insertion of

C7L gene resulted in re-establishment of the ability of the virus to prevent

apoptosis of host cells (Najera et al., 2006). C7L also plays a role in inhibiting
anti-viral responses by host cells that are induced by type I INF (Meng et al.,
2009).

Vaccinia Virus Ankyrin Repeat Gene B5R

B5R was first identified in VACV as a gene affecting host range and

viral plaque size in a temperature sensitive mutant of VACV, LC16m8.
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Nucleic acid sequence analysis of LC16m8 revealed that a single amino acid
was deleted from its sequence in comparison with the parental VACV strain

which resulted in early termination of the gene, resulting in loss of the gene
function (Takahashi-Nishimaki et al., 1991). VACV strain WR showed a

significant reduction in the production of extracellular enveloped virus (EEV)
particles when B5R gene was deleted. It also affected the viral plaque size and
virulence as compared to the parental strain (Wolffe et al., 1993). B5R, present
in VACV strain WR as a membrane protein is essential for trans-

Golgi/endosomal membrane wrapping of intracellular mature virus (IMV)
(Wolffe et al., 1993). Short consensus repeats (SCR) which are associated with
the complement control proteins superfamily are also found to be present in

the protein encoded by B5R. B5R encoded protein contains four short
consensus repeats (SCR) and deletion or mutagenesis of one or more of B5R

protein domains resulted in alteration of viral plaque size in vitro studies
(Mathew et al., 1998). B5R protein is well conserved among Orthopoxviruses

and orthologs are present in other poxvirus family members. Deletion of B5R
gene from RPXV resulted in the failure of plaque formation in otherwise
permissive cells like Vero, Pk-15, chicken embryo fibroblasts and QT-6.
(Martinez-Pomares et al, 1993) In a recent study, it has been indicated that
SCR4 domain of B5R protein binds and activates Src which is important for
the actin polymerization induced by VACV. (Newsome et al, 2004) VACV
strain LC16m8 is highly attenuated due to the mutation of B5R gene and B5R
is highly immunogenic which makes it an ideal vaccination agent against

VACV. Monkeys immunized with VACV strain LC16m8 showed no

symptoms when infected with MPXV strain Liberia or Zr-599 (Saijo et al.,
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2006).

Vaccinia Virus Ankyrin Repeat Gene E3L

E3L is another gene which regulates host range and pathogenesis of
VACV. It is known to play a role in anti-IFN mechanism used by VACV in

host immune system evasion along with another host range gene, K3L. E3L
encodes for a 25-kDa product which contains a double stranded RNA

(dsRNA) binding domain at the C-terminus and Z-DNA binding motif at the
N-terminus (Langland et al, 2006). As a response to viral infection, cellular

enzymes dsRNA binding protein kinase (PKR) and 2'-5' oligoadenyl synthase
inhibit protein synthesis in the host cell. PKR bound to dsRNA is

autophosphorylated and leads to phosphorylation of eIF-2 on the small a
subunit which results in the shutdown of protein synthesis (Williams, 1999).

A 2'-5' synthase shuts down the protein synthesis by activating a latent
endoribonuclease, which cleaves cellular mRNA and rRNA (Iordanov et al,

2000). E3L has also been shown to phosphorylate transcription factor IFN

regulatory factor 3 (IRF-3) and IRF-7 which blocks induction of IFN-a/p.
(Smith et al., 2001; Xiang et al, 2002).

As mentioned earlier, N-terminus of E3L protein binds with Z-double
stranded DNA which is essential for inhibiting PKR in an effective manner

(Kim et al., 2003; Kim et al., 2004; Langland and Jacobs, 2004). Deletion of 83
amino acids from the N-terminus of VACV strain WR resulted in significant

reduction in virulence in the mouse model (Brandt, and Jacobs, 2001). This

indicates that there is a strong correlation between the N-terminus of E3L
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protein and virulence. However, for full pathogenesis of VACV strain WR in
mice, both the C-terminus and N-terminus are necessary (Brandt, and Jacobs,

2001). The N-terminus of E3L does not appear to play any role in IFN
resistance mechanism and host range of VACV (Shors et al, 1997). VACV
demonstrated loss of ability to replicate in Vero, Hela and a murine

epidermis-derived cell line XS52 after deletion of E3L gene (Beattie et al,

1995; Langland and Jacobs, 2002; Deng et al, 2006) which indicates the role of
E3L as a host range gene. Host range function of E3L has also been
demonstrated in other poxviruses. MVA virus showed loss of replication

ability in CEF cells following E3L gene deletion due to the inhibition of viral
protein synthesis (Hornemann et al., 2003).

Mutant VACV with deletion of E3L gene showed accumulation of

cytoplasmic granules containing stress granule associated proteins G3BP,
TIA-1, USP10 and poly(A)-containing RNA around the viral factories at an
early stage of infection. These anti-viral granule (AVG) structures are

characterized by the absence of ribosomal subunits and are likely incapable of
translation. It is assumed that they are associated with restricted replication of

virus as they are seen in more than 80% of cells infected with mutant VACV

with E3L gene deleted. PKR and phosphorylated eIF2a are correlated with
formation of AVGs. Lack of PKR in mouse embryonic fibroblasts (MEFs)
resulted in a decrease of AVG formation, while a lack of eIF2a in MEFs

resulted in an absence of AVG formation (Simpson-Holley et al., 2011). NS1

gene in influenza virus has shown a functional similarity with E3L gene in
VACV. NS1 and E3L promote viral pathogenesis by interfering with IFN
mediated innate immune response. Mutant VACV with E3L gene deleted and
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NS1 gene inserted was able to promote viral replication in vitro by

preventing shutdown of protein synthesis, breakdown of RNA and
preventing apoptosis but failed to conserve the virulence in vivo. This
indicates that E3L and NS1 share some functional similarities as well as

differences (Guerra, 2011).

Vaccinia Virus Ankyrin Repeat Gene K3L

K3L is another host range gene which works through the same

mechanism as E3L gene. It prevents the phosphorylation of eIF2a by PKR
which has been demonstrated in vitro as well as in vivo studies (Davies et al.,

1992; Davies et al, 1993) and inhibits the protein synthesis shutdown.

Deletion of K3L gene in VACV strain Copenhagen demonstrated a wider
range of host as compared to the E3L knockout VACV, but was sensitive to
IFN in mouse L929 cells (Beattie et al, 1995). In a recent study it has been
demonstrated that K3L may not be playing a role in modulating disease

caused by VACV but possibly plays a key role in dissemination of VACV
from lungs to distal organs, but the exact mechanisms involved are not
completely known (Rice et al., 2011).

Cowpox Virus Ankyrin Repeat Gene CHOhr
CHOhr or CP77 is an ANK repeat protein encoded by CPXV025 gene

in CPXV. It is responsible for the ability of CPXV to replicate successfully in
Chinese hamster ovary (CHO) cells (Spehner et al, 1988). CHO cells are non-

permissive for VACV as early gene expression is prevented at an early stage
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of infection and host as well as viral protein synthesis is shutdown in an

extremely rapid manner (Drillien et al., 1978; Hruby et al, 1980).
Interestingly, CHOhr has shown functional equivalency with KIL and C7L

genes in VACV. Replication ability of VACV strain Copenhagen with both
KIL and C7L genes knocked-out, was successfully re-established in human

and porcine kidney cells when complemented with CHOhr (Perkus et al.,
1990). In another study, CHOhr/CP77 has been shown to bind with a host
cellular protein, HMG20A. In the absence of CP77, HMG20A protein
remained bound to the viral DNA of mutant VACV which lacked both KIL

and C7L genes but when CP77 gene was expressed in the same virus, CP77

protein bound to the HMG20A and removed away from viral clusters in
CHO-K1 cells. This suggests that CP77 binding with HMG20A plays an

important role in deciding the host range of virus in CHO-K1 cells (Hsiao et
al., 2006). Similarly, when CHOhr gene was inserted in Ectromelia virus

(ECTV), it extended the host tropism of ECTV to CHO cells (Chen et al.,
1992). CHOhr possibly acts by preventing early and sudden stoppage of
protein synthesis which otherwise occurs when CHO cells are infected with
VACV. CHOhr gene expression in VACV resulted in prevention of apoptosis
of the host cell and provided the virus longer duration for replication (Bair et
al, 1996; Ink et al., 1995). CP77 also plays a role in preventing the innate

immune response in host cells by suppressing NF-kB activation by TNF-a.
TNF-a is known to induce an innate immune response through activation of
NF-kB. CP77 modulates the innate immune response by interactions with p65

subunit of NF-kB through its N-terminal and SCF complex through Cterminal (Chang et al., 2009).

27

Serin Protease Inhibitor

Poxviruses encode several serin protease inhibitors (SPIs) which are
members of the serpin superfamily and are known to be involved in
inflammation and apoptosis. SPI-1, SPI-2 and SPI-3 are the three highly
conserved SIPs encoded by the Variolavirus (W), VACV, rabbitpoxvirus
(RPXV) and MYXV (Silverman, et al., 2001). SPI-1 affects the host range which

was evident by inability of SPI-1 knockout RPXV to replicate in pig kidney
cells and human lung carcinoma cells which otherwise are permissive for
RPXV (Ali,A.N„ 1994). SPI-1 appeared to inhibit proteinases of host cell

origin during RPXV infection that they act by inhibiting caspase-independent

apoptotic pathway (Brooks et al, 1995). SPI-1 in RPXV seems to inhibit
human neutrophil cathespin G and along with SPI-2, inhibits granulemediated cell killing pathways (Macen et al., 1996a; Moon et al, 1999). SPI-2
appears to inhibit proteolytic activity of interleukin ip converting enzyme,
granzyme B and block apoptosis induced through Fas receptor or type 1 TNF
receptor (Dobbelstein and Shenk, 1996; Macen,et al, 1996b; Kettle et al., 1997).
Role of SPI-3 in inhibiting apoptotic pathways has not been yet established.
VACV with both the SPI-1 and SPI-2 deletions has shown better growth in

transformed cells or p53-null cells as compared to normal cells. This
selectivity of replication can be attributed to the loss of the anti-apoptotic
property of VACV due to the absence of SPI-1 and SPI-2 (Guo et al., 2005).

Ankyrin Repeat Gene p28/N!R

Protein p28/N!R is a well

conserved zinc-finger protein in
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Orthopoxviruses and most of the Chordopoxviruses encode orthologous

proteins. It is expressed in cytoplasm during early stages of viral infection
(Senkevich. et al, 1994). Protein p28/NlR from many Orthopoxviruses has
exhibited ubiquitin ligase activity (Huang et al., 2004; Nerenberg et al, 2005).

Ubiquitin and p28/NlR co-localize in cytoplasm of the host cell and the antiapoptotic activities by p28/NlR are possibly executed through the
ubiquitination of host proteins (Nerenberg et al, 2005). In ECTV p28/NlR
has demonstrated anti-apoptotic activity in host cells induced by UV light
(Brick et al., 2000). ECTV virulence was affected to a great extent in murine

models by non-expression of p28/NlR, however its replication ability was
least affected in most of the cell lines tested (Senkevich et al., 1994). Murine

macrophages proved as an exception, where p28/NlR knockout ECTV was

able to express early genes but failed to replicate later, resulting in failure of
successful viral infection (Senkevich et al, 1995). Though the exact

mechanism of action through which p28/NlR acts is not clear, the
experimental studies suggest a possibility of p28/NlR playing an essential
role in viral DNA replication. Infection of poxviruses is significantly affected
by proteasome inhibitors. Late gene expression and viral DNA replications
seems to be mainly affected as the cytoplasmic viral factories fail to appear,
but early gene expression is unaffected. Ubiquitin-activating enzyme

inhibitors affect the early and late protein expression during viral infection.
Though the exact molecular targets involved in the process are not known, it

is quite clear that a functional proteasome system in the host cell is very much
required for poxvirus replication (Zhang et al., 2009).
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Myxoma Virus Ankyrin Repeat Gene M-T2

M-T2 is a host range gene encoded by MYXV which is believed to

promote viral replication by inhibiting apoptosis of host cells. M-T2 knockout
MYXV was able to replicate in RK13 cells but failed to establish successful

infection in rabbit T-lymphocytes in vitro, as the virus failed to prevent the

rapid apoptotic response by the host cell triggered by the infection. Infection
of RL-5 cells by M-T2 knockout MYXV resulted in an abortive infection even

after supplementing exogenous M-T2 indicating towards the possibility of
intracellular form of M-T2 blocking TNF mediated apoptosis (Macen et al,

1996b). It has been demonstrated that intracellular M-T2 inhibits cellular

TNFR signaling by the formation of a complex with cellular TNFR through
preligand assembly domain (PLAD) which is distinct from TNF binding
domain site. This phenomenon has also been demonstrated in human cells
indicating that it is not restricted to a single species (Sedger et al., 2006).
M-T2 has also been correlated to the virulence of MYXV as M-T2

knockout MYXV showed a significant attenuation as compared to the

parental virus when used to infect European rabbits. Most of the rabbits
launched an effective immune response against M-T2 knockout MYXV and

recovered completely. M-T2 also encodes for a secretory form of protein
which shares the sequence similarity with the N-terminus of cellular TNFR
and acts as a viroceptor (Upton et al., 1991). M-T2 inhibits the cytolytic
activity of rabbit TNF by binding with it. It has been demonstrated that M-T2

has high affinity for TNF (Schreiber and McFadden, 1994; Schreiber et al.,
1996).
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Myxoma Virus Ankyrin Repeat Gene M-T5

MYXV encodes an ANK repeat host range protein named as M-T5. It is

a 49-kDa protein which is expressed throughout the course of viral infection
(Mercer et al, 2005; Johnston, 2005; Mossman et al., 1996). M-T5 has been
shown to affect the ability of MYXV to replicate in different cell lines in vitro.
M-T5 knockout MYXV has been able to infect RK-13 cells just like parental

virus, but it showed an inability to establish a successful infection in RL-5
cells. Failure of infection in RL-5 cells by M-T5 knockout MYXV resulted in
the shutdown of host and viral gene synthesis and the induction of apoptosis

(Mossman et al, 1996). This Indicates that M-T5 possibly inhibits the
shutdown of protein synthesis and induction of apoptosis and helps MYXV to
establish infection in T-lymphocytes and spread to the distant sites (Mossman
et al., 1996).
M-T5 also works as a virulence factor as demonstrated by in vivo

studies. M-T5 knockout MYXV failed to establish myxomatosis when used to
infect rabbits. Rabbits were able to launch an immune response against M-T5

knockout MYXV and recovered completely. M-T5 forms a complex with a

cellular component which increases the ubiquitination of p27/Kipl, which is

a cell cycle inhibitory factor. Infection with M-T5 knockout MYXV results in
the arrest of cell cycle at G0/G1 stage as a response by host cells, but wildtype MYXV prevents the cell cycle arrest and promotes cell cycle progression
beyond G0/G1 (Johnston et al., 2005). M-T5 has been shown to bind and
promote phosphorylation of Akt protein which is a serine-threonine kinase,
essential for many critical cellular signaling pathways. Many human cancer
cell lines express low levels of phosphorylated Akt and M-T5 helps MYXV to
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expand its ability to infect a wide range of human cancer cell lines by
increasing phosphorylation of Akt (Wang et al., 2006).

Many other known genes playing role in determination of host range
have been identified in the poxviruses, but the exact mechanisms utilized by
these genes are largely unknown and need to be studied further.
Oncolytic Viruses

In spite of significant advances in surgical treatment and

chemotherapy over the last few decades, cancer remains one of the leading
causes of death all over the world. Advances in surgical treatment and

chemotherapy have improved the survival rate in patients with advanced
cancer, but controlling the disease progression and the recurrence of cancer is

still a major issue. Novel options of cancer treatment are an essential need for
our time and oncolytic virotherapy has shown some promising results.
Oncolytic effect of viruses was a coincidental finding in 19th century
when viral infections appeared to help in regression of some hematological
cancers. A woman who was a known case of cervical carcinoma showed

regression of the disease when inoculated with a rabies virus. It has been
noted that viruses like VACV, Reovirus and New Castle Disease virus

(NCDV) preferentially infect cancer cells over the normal cells (Kelly and
Russell, 2007).

In the process of the development of an efficient oncolytic virus, a key
step is to uncover the functions of different viral genes. A better
understanding of functionality of viral genes will be helpful to decide on
which viral genes can be manipulated or used as exogenous genes to
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construct an effective oncolytic virus. Some of the mechanisms through which

oncolytic viruses work include cell death by either by direct lysis following
viral replication or due to cytotoxicity caused by the viral proteins.

Adenovirus proteins E3 and E40RF4 are known to cause cell death by

inducing toxicity (Tollefson et al., 1996). Another mechanism of action used

by oncolytic viruses is induction an immune response against tumor cells,
leading to the destruction of cells. Following the viral infection, the cancer
cells secrete cytokines and growth factors which induce an initial trigger
immune response, which in turn establish a full-fledged immune response

involving cytotoxic T lymphocytes against the cancer cells (Toda et al., 1999).
Oncolytic viruses can increase the sensitivity of the tumor cells to

chemotherapy or radiotherapy. ElA gene in adenovirus has been shown to be

responsible for the upregulation of the p53 function in the tumor cells with
intact p53 gene, following chemotherapy and radiotherapy (Martin-Dugue et
al., 1999).

Though many oncolytic viruses have shown promising results and can
be used as a treatment option for cancer, there many obstacles that needed to

be cleared. Use of oncolytic virotherapy has been limited by number of
factors like host immune response against virus, lack of specificity against
cancer cells and inefficient viral delivery at the target site and toxicity. Using

the modern genetic engineering technology, researchers are trying to
overcome the hurdles in the path of use of oncolytic viruses as an efficient

treatment option for cancer by using different strategies. One of the strategies
used to increase the specificity of oncolytic viruses and enable them to infect
the cancer cells is deletion of the genes from the virus genome whose
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expression is usually upregulated specifically in the cancer cells. Deletion of

thymidine kinase (TK) gene is a strategy used on the similar line. Absence of
TK gene in the viral genome makes the virus dependent on host cell TK for its
growth. This strategy has been used to generate an oncolytic virus HPSV1

genome to enable herpes simplex virus type 1 (HPSV1) to selectively grow in
the cancer cells (Martuza et al., 1991). Deletion of genes responsible for the
virulence is another strategy used to modulate the oncolytic viruses, in an

effort to minimize the damage to the normal cells. HPSV1 mutant NV1020 is

an oncolytic virus which has been modulated by deletion of one copy of each
of the diploid genes aO, a4, yi34.5 and UL56from the viral genome has shown

promising results, when used in the treatment of hepatic cancer (Kelly et al.,
2008). In a similar pattern to increase the target specificity, E1B gene was
deleted from the adenovirus to interfere the late viral RNA export, restricting

adenovirus growth in normal cells (O'shea et al., 2004). Insertion of
transgenes into the viral genome to express the exogenous gene products
favoring viral growth in cancer cells and modulating the host immune
response against the virus are relatively new strategies which appear
promising, opening new doors to improve the efficiency of oncolytic
virotherapy (Cheever, 2008). Insertion of promoter sequences of the specific
genes that are upregulated in the cancer cells into the viral genome can
enhance the ability of virus to selectively replicate in cancer cells. Promoter
sequences of carcinoembryonic antigen in HPSV-1 genome and alphafeto
protein, prostate-specific antigen and MUC1 genes in adenovirus genome
have been inserted to increase their target specificity and have shown

encouraging results (Reinblatt et al., 2004; Hallenbeck et al., 1999; Yu et al.,
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1999; Kurihara et al., 2000). Following the insertion of these promoter

sequences in the viral genome, HPSV-1 showed a better replication ability in
colorectal cancer cells and adenovirus showed selectively enhanced

replication in hepatic, prostate and breast cancer cells. Two major routes of
administering the oncolytic viruses are intratumoural and intravenous (IV).
The intratumoural route has been tried with limited success to treat easily

reachable solid tumors. Virus injected intratumourally needs to replicate in
the tumor tissue and then disseminate through circulatory system to the

distant metastatic sites. This provides the time and opportunity to the host to

develop an immune response against the virus. This limits the chances of
intratumoral virus targeting metastatic sites which is a major concern. On the
other hand, IV administration of viruses provides the opportunity to the virus

to target primary as well as distant metastatic tumors at the same time.
However, IV route also has some obstacles like host immune response

(Shashkova et al., 2008), nonspecific uptake by the lung, liver and spleen, and
poor viral delivery into the extravascular compartment.

Viruses that are present ubiquitously in nature or have been used for
vaccination cannot be used as oncolytic viruses, as most of the population has

immunity against them. Similarly use of the same oncolytic virus for the
second time will be ineffective in the same patient due to the development of

an immune response against the virus during the first use. This makes it

necessary to develop more oncolytic viruses. Viral genes regulating the host
or tissue tropism can possibly be manipulated to expand the horizon of
available options to develop oncolytic viruses.
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MATERIALS AND METHODS
Cells and Virus

Owl monkey kidney (OMK) cells, colorectal cancer cell lines (WiDr,
LS513, SW1463) and human fetal lung fibroblasts (WI-38) were obtained from

American Type Culture Collection (ATCC). Colorectal cancer (HCT-116) and
malignant melanoma (SK-MEL-5) cell line were received from Dr. McFadden
as a gift. OMK cells were cultured in growth medium, Eagle's minimum
essential medium (EMEM) (Sigma-Aldrich) supplemented with 10% (v/v)
newborn calf serum (Atlanta Biologicals, Lawrenceville, GA), 1.5 g/L sodium
bicarbonate, 2 mM L-glutamine, and antibiotics (Penicillin G sodium 100

units/ml, streptomycin sulfate 100 (ig/ml) (Invitrogen). OMK cells after
infection were maintained in maintenance medium, EMEM supplemented

with 2% (v/v) newborn calf serum, 1.5 g/L sodium bicarbonate, 2 mM L-

glutamine, and antibiotics (Penicillin G sodium 100 units/ml, streptomycin
sulfate 100 ug/ml). All the cancer cell lines (HCT 116, SK-MEL-5, WiDr,
SW1463, LS513) and WI-38 were grown in growth medium, Dulbecco's

modified eagle medium (DMEM) (Gibco) supplemented with 10% (v/v) fetal
bovine serum, 1.5 g/L sodium bicarbonate, 2 mM L-glutamine, and
antibiotics (Penicillin G sodium 100 units/ml, streptomycin sulfate 100

Ug/ml). All the cancer cell lines (HCT-116, SK-MEL-5, WiDr, SW1463, LS513)
and WI-38 after infection were maintained in maintenance medium, DMEM

supplemented with 2% (v/v) fetal bovine serum, 1.5 g/L sodium bicarbonate,
2 mM L-glutamine, and antibiotics (Penicillin G sodium 100 units/ml,
streptomycin sulfate 100 u.g/ml). All the cell lines were incubated at 37°C in
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humidified incubators with 5% CO2. TPV-Kenya was obtained from Dr.
Joseph Esposito.

Generation of pPoxCherry-AT146R Plasmid

Vector p-mCherry was purchased from Clontech which

contains mCheery reporter gene. The mCherry cassette was cloned into

pBlueScript II (KS+) plasmid followed by insertion of a single early late

synthetic poxvirus promoter into the plasmid to create pPoxCherry plasmid.
The DNA sequences flanking the left and right sides of T146R ORFs were

amplified by PCR using TPV-Kenya genomic DNA as a template. Primers
used for the upstream and downstream flanking regions of T146R ORF are
listed in Table 1. Following amplification by PCR, the left flanking DNA

segment was treated with restriction endonucleases Xhol and Clal, while the
right flanking DNA segment was treated with restrictionendonucleases NotlHF and Sacl-HF for 3 hours at 37°C. Vector, Plasmid pPoxCherry was treated
with restriction endonucleases Xhol and Clal in the same manner as insert

T146R left flank and both the vector and insert were gel purified. T146R left

flank and pPoxCherry plasmid were mixed in approximately 3:1 ratio, along
with T4 DNA Ligase (Invitrogen) enzyme and the ligation reaction mixture

was incubated at room temperature for one hour to clone the insert into the
vector. T146R left and right flanking regions were cloned into pPoxCherry

plasmid (Fig. 1) between Xhol-Clal and Notl-Sacl restriction sites respectively
to obtain pPoxCherry- AT146R plasmid. Confirmation of the cloning of T146R
left and right flanking regions into the plasmid was done by colony PCR,
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using the respective primers. Plasmid pPoxCherry-AT146R was treated with
the restriction enzymes at 37°C for 3 hours to cut the left flank with Xhol and
Clal, and the right flank with Notl-HF and SacI-HF. Presence of the left and

right flanking regions was confirmed by agarose (l%w/v) gel electrophoresis,
stained with ethidium bromide (0.5ng/ml).

Table 1

List of primers used to amplify flanking regions of T146R by PCR.
Underlined sequences indicate the restriction sites for the endonucleases
Xhol. Clal, Notl and Sad.
146R-left/for-XM

GGATATCTCQAGAGTTTATGTGTAAGT

146R-left/rev-C/flI

GT AAAAT ATCGATGTCATTTTTAGTATATTG

146R-right/for-NofI

CanAATAAATAQCGGCCGCATTTAATACC

146R-right/rev-Sfld

CATCTTGAGCTCTTGATCCTCTTGC

Generation of Recombinant TPV-AT146R

OMK cell monolayers were grown in EMEM growth medium in a 35
mm Petri-dish. Approximately 80% confluent OMK cell monolayer was

infected with TPV-Kenya by adsorbing the virus at room temperature for one
hour at the multiplicity of infection (pfu/cell) of 1. The virus was removed
following the adsorption and 2 ml of EMEM maintenance medium was
added. After incubating the Petri-dishes at 37°C for one hour, cells were
transfected with 1 fig of pmCherry-AT146R plasmid DNA using jetPRIME

transfection reagent (Polypus-transfection) as per the manufacturer's
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instructions. Following Incubation of the transfected cells for 4 hours at 37°C,
the medium was completely removed and overlay EMEM maintenance

medium with 0.5% methylcellulose was added gently along the wall of the
Petri-dish to prevent any damage to the monolayer. At 96 hours posttransfection, isolated viral plaques expressing red colored m-Cherry protein

were identified, picked and plaque purified by passing through four cycles of
plaque purification. Deletion of T146R ORF from the recombinant virus TPVAT146R obtained through the process summarized in figure 2 was confirmed

using the internal primers for T146R ORF. Internal primers for T146R are
listed in Table 2. TPV-Kenya genomic DNA was used as a template to design
internal primers for T146R ORF.

Table 2

List of T146R internal forward (for) and reverse (rev) primers
T146R-

internal/for

GATAAAAAAAATAACGTTAATGAAATTTATAGGGG

T146R-

internal/rev

CGTTAATTTTTTTCCCATATATAATAGAGTTTC
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mCher

Poxvirus promoter

eft flank (Xhol-Clal)

Right flank (Notl-Sacl]t

M13 reverse primer binding '^ \

Jac Promoter

pUC origin

f1 (+) origin

Figure 1

Map of pPoxCherry. Plasmid constitutes a synthetic poxvirus promoter and
mCherry reporter gene. Sites of insertion for T146R left and right flanking
sequences are indicated on either side of mCherry reporter gene.
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pBlueScript II (KS+) Plasmid
mCherry

plasmid
Poxvi rus

promoter

ligation

'!<ap:''

pPoxCherry plasmid

T146Rleft +

right flank
ligation

1

pPoxCherry-AT146R plasmid

Transfection
- Infection

Figure 2

Overview of construction of TPV-AT146R virus. Synthetic poxvirus promoter

and mCherry cassette were cloned into pBSII(KS+) plasmid to create
pPoxCherry plasmid. Left and right flanks of T146R ORF were ligated into
the pPoxCherry plasmid to obtain pPoxCherry- AT146R plasmid which was
transfected into TPV-Kenya to create the recombinant TPV- A146R.
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100X Virus Concentration

Following infection of OMK cells with TPV-AT146R virus, the
monolayer showed cytopathic effect (CPE) at around 5 days post infection,
and mCherry protein was expressed which could be observed under UV light
as shown in Figure 3. Multiple roller bottle 490cm2 flasks were used to grow
TPV-AT146R in larger quantities. OMK cells were grown in roller bottle 490
cm2 flasks in minimum essential medium eagle with Hank's salt (HMEM)

supplemented with 10% (v/v) newborn calf serum, 1.5g/L sodium
bicarbonate, 2mM L-glutamine, and antibiotics (Penicillin G sodium 100

units/ml, streptomycin sulfate 100 (ig/ml). OMK monolayer was infected
with the TPV-AT146R when they were about 80% confluent and maintained
in HMEM with 2% (v/v) newborn calf serum, 1.5g/L sodium bicarbonate,

2mM L-glutamine, and antibiotics (Penicillin G sodium 100 units/ml,
streptomycin sulfate 100 fig/ml). All roller bottle flasks were kept at 37°C on
a roller apparatus. The OMK cell monolayer was completely destroyed in 710 days after infection. The infected culture was collected and centrifuged at
1500 x g for 20 minutes at 4°C to separate cells. The cell pellet was resuspended in sterile deionized water and left at 4°C overnight. The cell pellet
was freeze thawed 3X and centrifuged at 1500 x g for 20 minutes at 4°C. After
collecting the supernatant, the cell pellet was re-suspended in sterile
deionized water and subjected to sheer force with a homogenizer (20 strokes)
and centrifuged at 1500 x g for 20 minutes at 4°C. All the supernatant

collected following every centrifugation was pooled and ultracentrifuged
using Beckman Ti45 rotor at 125,000 x g (40,00rpm) for 90 minutes at 4°C The
virus pellet was soaked in EMEM maintenance medium overnight at 4°C and
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re-suspended later to store at 4°C or -20°C.

Plaque Assay

Viral titers were determined by plaque assay using serial dilutions of
virus. OMK cell were plated in 6-well plates at a density of lxlO6 cells per
well and the monolayer was infected with 300 ul of dilutions from 10"4 to 10"7
of the virus. The virus was adsorbed over the OMK monolayer for 1 hour at

room temperature (RT) and removed from the well. Two milliliter of EMEM
maintenance medium with 0.5% methyl cellulose was added to each well of

the 6-well plate. After 9 days of incubation at 37°C, medium was removed
from the wells carefully and monolayer was stained for 1 hour with 0.1%

(w/v) crystal violet in 10% formaldehyde (plaque staining solution). After
removing the staining solution, the wells were rinsed with water and airdried and plaques were counted in each dilution to determine the plaque
forming units per milliliter.

Infection of Cell Lines with TPV-AT146R

OMK, WI-38, HCT-116, SW1463, WiDr, LS513 and SK-MEL-5 cells

were planted in a 12 well plate at a density of lxlO5 cells per well. The
monolayers were infected with TPV-AT146R at 1 pfu/cell in 100 pi medium
by adsorbing the virus over the monolayer for 1 hour at RT. The virus was
removed and 1.0 ml of DMEM maintenance medium was added to all the

wells except the well with OMK cells, which received 1.0 ml of EMEM
maintenance medium. The plates were incubated at 37°C for 96 hours in a
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humidified incubator with 5% C02. Microscopic examination of infected cells
was carried out for CPE.
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RESULTS

Conservation of Ankyrin Repeat Protein T146R in Poxviruses

ANK repeat protein T146R was compared with other poxvirus ANK

repeat proteins. BLAST result of the ANK repeat protein T146R indicated that
the YLDV (146R), YMTV(146R), DPXV W848-83 (DpV83gpl64), Swinepox

virus (SPV142), MYXV (M149R), Lumpy skin disease virus (LSDV) NI-2490

(LSDV142) encoded ANK repeat proteins share 98%, 75%, 42%, 38%, 34% and
38% similarity respectively. Multiple sequence alignment data of all the above
mentioned proteins showed conservation of many amino acids as shown in
Figure 3.

Construction of Mutant Virus TPV- AT146R

T146R left and right flanks were ligated in the pPoxCherry plasmid
which carried mCherry reporter cassette. T146R left and right flanks and the

mCherry cassette were successfully cut from the plasmid pPoxCherry-T146R

using appropriate restriction enzymes and analyzed by DNA gel
electrophoresis, which confirmed the ligation of the T146R left (868bp) and
right (564bp) flanks in the plasmid as shown in Figure 4. T146R left flank was
cut with restriction enzymes Xhol and Clal, while T146R right flank was cut
with restriction enzymes Nofl-HF and SacI-HF.
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Figure 3

Multiple sequence alignment of TPV (146R), YLDV (146R), YMTV (146R),
DPXV W848-83, SPV (SPV142), MYXV (M149R), LSDV NI-2490 (LSDV142).
Conserved amino acids are color coded based on their nature. Green -

Polar/Hydrophilic: N T S Q, Blue - Hydrophobic: L V I M F W A C, Violet Acidic: D E, Red - Basic: K R, Magenta - Large aromatic polar: H Y
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Figure 4

Agarose gel DNA electrophoresis of T146R left and right flanks cut from the
pPoxCherry-AT146R plasmid. Plasmid pPoxCherry-AT146R was treated with
restriction enzyme pairs Xhol-Clal, Notl HF-SacI HF and Clal-Notl HF to cut
the T146R left flank (lane a), mCherry cassette+synthetic poxvirus promoter
(lane b) and T146R right flank (lane c) respectively. Plasmid pPoxCherryAT146R was treated with respective restriction enzymes for 3 hours at 37°C
and run on agarose (l%w/v) gel stained with ethidium bromide (0.5ng/ml).
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The T146R gene from TPV-Kenya genome was replaced with T146R

left and right flanks along with mCherry cassette by homologous
recombination.

Mutant

TPV-AT146R

was

constructed

by

infection-

transfection with TPV-Kenya and pPoxCherry-AT146R plasmid on OMK cell

monolayer. Expression of mCherry reporter gene facilitated the isolation of
mutant TPV-AT146R plaques which were clearly visible under ultraviolet

(UV) light as red colored plaques as shown in Figure 5. TPV-AT146R was
purified through three cycles of plaque purification.
To confirm the knockout of T146R gene from TPV- AT146R genome,

genomic DNA of TPV-AT146R was extracted by phenol-chloroform extraction

technique. Internal primers for the T146R (Table 2) were used to amplify
T146R ORF, using TPV- AT146R DNA as a template. No amplification of
T146R ORF was noted as shown in Figure 6, which confirmed the knockout of
T146R gene from the mutant TPV- AT146R genome.

During infection-transfection process, the segment of pPoxCherryAT146R plasmid which only includes T146R left and right flanking sequences

along with the poxvirus promoter and mCherry cassette is supposedly
incorporated into the TPV-Kenya genome during a double crossover

homologous recombination event as shown in Figure 7(a). In the event of the
possible single crossover recombination, the entire pPoxCherry-AT146R
plasmid including ampicillin resistance (ampR) gene may get incorporated
into the viral genome as shown in Figure 7(b). To rule out the possibility of
single crossover recombination event, PCR amplification of ARG was
attempted using the recombinant TPV-AT146R genomic DNA as a template.
No amplification of the ARG fragment from TPV- AT146R genome was
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noticed as shown in Figure 8. This confirmed the absence of ARG in the TPV-

AT146R genome which in turn assured that the T146R gene was knocked out
by a double crossover homologous recombination event as shown in Figure
7(a).

Light

Fluorescence

Figure 5

UV fluorescence microscopy of TPV- AT146R infected OMK cells at day 4
post infection- transfection.
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Figure 6

PCR analysis of T146R ORF amplification from TPV- AT146R genomic DNA.
T146R internal primers were used to PCR amplify T146R ORF fragment from
TPV- AT146R genomic DNA and TPV- Kenya genomic DNA. T146R ORF
amplification was not seen from TPV- AT146R genomic DNA (lane a), but
T146R ORF was successfully amplified from TPV-Kenya genomic DNA (lane
b). T66R ORF fragment was successfully amplified from both TPV-AT146R
(lane c) and TPV- Kenya (lane d) genomic DNAs.
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Figure 7

T146R gene knockout from TPV-Kenya genomic DNA. (a) Schematic map of
TPV-Kenya genome and the plasmid pPoxCherry-AT146R designed for
deletion of T146R gene. TPV-Kenya DNA sequences adjacent to T146R
(T146R left and right flanks) were cloned along with poxvirus promoter and
mCherry cassette into the TPV-Kenya DNA by double crossover homologous
recombination, (b) Schematic map of TPV-Kenya genome and the plasmid
pPoxCherry-AT146R showing the possible single crossover homologous
recombination event in which the entire plasmid pPoxCherry-AT146R

including ampR gene can get cloned into TPV-Kenya DNA while knocking
out T146R gene.
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Figure 8

PCR analysis of absence of ampicillin resistance (ampR) gene from TPVAT146R genome. Internal primers for ampR gene were used to PCR amplify
the ampR gene fragment from TPV-AT146R DNA (lane a) and pBSII (+KS)
plasmid (lane b). Negative control sample PCR was run without any vector
(lane c).

52

Replication of TPV- AT146R in Human Cancer Cell Lines

TPV- AT146R replication in different human colorectal cancer cell lines
(WiDr, LS513, SW1463, and HCT 116) and human malignant melanoma (SKMEL-5) was studied. Human lung fibroblasts (WI-38) and OMK cells were

also used in the study as control. All cells used in the study were planted in

12-well plates at an approximate density of 1 x 105 cells per well and the cell
monolayers were infected with TPV- AT146R and TPV-Kenya at 1 pfu/cell.
Cell monolayers were observed for the expression of mCherry under
fluorescent microscopy and CPE, at 96 h.p.i. Although mCherry expressing
cells were observed in all the TPV-AT146R infected cell lines (Figure 9A,

Figure 9B and Figure 9C), marked CPE was only noted in OMK, WI-38 and
HCT116 cells, but not in LS513, SW1463 and WiDr cells (Table 3). These

results suggest that virus replication did occur in all cell lines.
OMK cells were permissive to both TPV-AT146R and TPV-Kenya as

shown from the marked CPE. Similarly, CPE was also observed in WI-38 cells
infected with TPV-AT146R and TPV-Kenya.

Amongst colorectal cancer cell lines, only HCT 116 showed

pronounced CPE, at 96 h.p.i. following the infection with TPV-AT146R and
TPV-Kenya. No marked CPE was observed after infection of LS513, SW1463
and WiDr cells with TPV-AT146R and TPV-Kenya as compared to HCT 116.

Human malignant melanoma (SK-MEL-5) cells also supported TPV-AT146R
replication. SK-MEL-5 demonstrated CPE at 96 h.p.i. following infection with
TPV-AT146R.

Since all cell lines used in the experiment demonstrated red colored

virus plaques at 96 h.p.i, following infection with TPV- AT146R, it indicates

that the ankyrin repeat gene T146R in the tanapoxvirus genome is not an
essential gene for the replication of virus in cell cultures.

Table 3

Microscopic observation of TPV- AT146R infected cells at 96 h.p.i. OMK cells,
human fetal lung fibroblasts (WI-38), human colorectal cancer cell lines
(LS513, HCT 116, SW1463, WiDr) and human malignant melanoma cells (SKMEL-5) were infected with TPV- AT146R and the cell monolayers were
observed at 96 h.p.i. under Nikon Diaphot 300 epifluorescence microscope at
100X magnification.

Cytopathic effect

OMK

++

WI-38

++

HCT 116

++

LS513

+

SW1463

+

WiDr

+

SK-MEL5

+
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Figure 9A

Replication of TPV-AT146R in OMK cells, human fetal lung fibroblasts (WI38) and human colorectal cancer cell line (HCT 116). Cells were infected with
TPV- AT146R at 1 pfu/cell, fluorescence and phase contrast images of the
infected monolayers were captured at 96 h.p.i. Images were taken using a 35
mm camera on a Nikon Diaphot 300 epifluorescence microscope at 100X
magnification.
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Figure 9B

Replication of TPV- AT146R in human cancer cell lines (LS513, WiDr). Cells
were infected with TPV- AT146R at 1 pfu/cell, fluorescence and phase
contrast images of the infected monolayers were captured at 96 h.p.i. Images
were taken using a 35 mm camera on a Nikon Diaphot 300 epifluorescence
microscope at 100X magnification.
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Figure 9C

Replication of TPV- AT146R in human cancer cell lines (SW1463, SK-MEL-5).
Cells were infected with TPV- AT146R at 1 pfu/cell, fluorescence and phase
contrast images of the infected monolayers were captured at 96 h.p.i. Images
were taken using a 35 mm camera on a Nikon Diaphot 300 epifluorescence
microscope at 100X magnification.
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DISCUSSION

Cancer remains a major health concern, being one of the leading causes
of death all over the world. Certain oncogenes like HER-2/ neu/erbB2
(Tsapralis et al., 2012), c-Myc (Wolfer, 2011), Cyclin Dl (Kim, and Diehl,
2009), EGFR (Brand et al., 2011) are known to be altered leading to the

development of different types of cancer. Mutational inactivation of the
tumor suppressor genes p53 (Greenblatt et al., 1994), BRCAl (Somasundaram
et al., 1997), pl6 and Rb (Gorgoulis et al., 1998) leads to a loss of control over

the cell growth and has been linked with the different types of cancer. These

genes exhibit the oncogenic activity through complex processes, some of
which has been understood up to certain extent. However the exact
mechanisms involved in the oncogenesis are largely unknown.

Novel effective treatment options for cancer need to be developed due

to the high mortality associated with cancer and limitations of conventional
treatment options like surgery, radiotherapy and chemotherapy. Oncolytic
virotherapy is a relatively new treatment option for cancer and is still in its
primitive stages. Rapid clearance from the system, target specificity,
efficiency and host immune response are some of the limitations which
restrict the use of oncolytic virotherapy in an effective manner. Number of
viruses like HPSVl, VACV, adenovirus, NCDV, reovirus and many more are

being used to develop oncolytic viruses (Kelly and Russell, 2007). TPV can be
developed into an efficient oncolytic virus as some of the advantages
associated with TPV are that humans are one of its known natural hosts

(Espana et al., 1971). In addition, TPV causes only mild febrile disease in
humans which is self-limiting (Downie et al., 1971), making it comparatively

58

safer to use in humans. Our lab has been involved in performing growth

studies of TPV and its temperature sensitive mutant variants in different cell

lines including human cancer cell lines. Previous studies in our lab have
established the growth characteristics of TPV in various primate cell lines,
like African green monkey kidney cell lines, OMK cells, human lung
fibroblasts, human laryngeal epidermoid cancer cells and human cervical
cancer cells (Mediratta and Essani,, 1999). TPV demonstrated the best
replication ability in OMK cells.

In order to develop an oncolytic virus it is necessary to study its

growth characteristics. Role of the ANK repeat genes in determination of the
cell tropism and host range of viruses is well documented. In some cases,

ANK repeat genes play role in determining the permissiveness of viruses into

certain cell types through manipulation of the host immune response to avoid
cell death and provide the necessary time for viral replication (Mohamed at
al., 2009). Some ANK proteins can manipulate the host cell's ubiquitin system

by directing it towards specific proteins and thus providing the virus the
opportunity to grow (Sonnberg et al., 2008). MYXV ANK repeat gene M-T5
has been demonstrated to interact with cellular pathways to regulate the cell

cycle (Johnston et al., 2005). Other ANK repeat proteins act by inhibiting
cellular apoptotic pathways to provide the opportunity to the virus to grow
(Brooks et al., 1995).

In order to develop TPV as an oncolytic virus, it is essential to study

the role played by the ANK repeat genes in determination of the cell tropism.
TPV genome has been completely sequenced and carries six ANK repeat

genes, namely T8L, T11.1L, T11.2L, T146R, T147R and T148R. This study was
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aimed at understanding the role of T146R gene in virus replication in various
human cancer cell lines. The recombinant TPV-AT146R which lacks the T146R

ANK repeat gene replicated in monkey cells (OMK) and human fetal lung
fibroblasts (WI-38) as CPE was visible following infection with TPV-AT146R.

Additionally, human colorectal cancer cell lines as well as human malignant
melanoma cells also demonstrated red colored plaques after infection with
TPV-AT146R. Marked CPE was observed in HCT 116 cells, but LS513,

SW1463 and WiDr cells demonstrated no pronounced CPE. It indicates that

absence of the ankyrin repeat gene T146R from TPV genome has a potential
to affect the replication ability of the virus in LS513, SW1463 and WiDr.

Though it appears that T146R is not an essential gene for the replication of
virus and didn't seem to affect the permissiveness in the cell lines used in the

experiment, a possibility of presence of other functionally equivalent gene in

TPV genome needs to be investigated. The ANK repeat genes C7L and KIL in
VACV strain Copenhagen demonstrated functional equivalency in terms of
anti-interferon activity of the virus (Meng et al., 2009).

However, to investigate a possible role played by T146R gene in TPV,
in determination of cell tropism, the replication cycle of TPV-AT146R in

different cells including a panel of human colorectal cancer cells need to be
studied. The human colorectal cancer cell lines to be used in the experiment
include the cells derived from different sites of the colorectal tract. Cell line

LS513 is derived from a Duke's type C, mucin secreting cecal tumor (Suardet

et al., 1992). Cell line SW1463 is obtained from Duke's type C, rectal
adenocarcinoma (Leibovitz et al., 1976). Cell lines HCT116 and WiDr are
derived from colon (Brattain et al., 1981; Noguchi et al, 1979). In addition,
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future studies include the investigation of the role of other ANK repeat genes
T8L, T11.1L, T11.2L, T147R and T148R in TPV in determining cell tropism.

Difference in the ability of any virus to replicate in different cell lines can be
attributed to a number of factors within the cell. These factors vary from cell

surface receptors to number of different biochemical pathways. Additional
studies are needed to understand the quantitative variability of virus
replication in different cell lines.
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